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ABSTRACT
The basal mitochondrial transcription machinery is
essential for biogenesis of the respiratory chain and
consists of mitochondrial RNA polymerase, mito-
chondrial transcription factor A (TFAM) and mito-
chondrial transcription factor B2. This triad of
proteins is sufficient and necessary for mtDNA tran-
scription initiation. Abolished mtDNA transcription
caused by tissue-specific knockout of TFAM in the
mouse heart leads to early onset of a severe mito-
chondrial cardiomyopathy with lethality within the
first post-natal weeks. Here, we describe a mouse
model expressing human TFAM instead of the en-
dogenous mouse TFAM in heart. These rescue mice
have severe reduction in mtDNA transcription initi-
ation, but, surprisingly, are healthy at the age of 52
weeks with near-normal steady-state levels of tran-
scripts. In addition, we demonstrate that heavy-
strand mtDNA transcription normally terminates at
the termination-associated sequence in the control
region. This termination is abolished in rescue
animals resulting in heavy (H)-strand transcription
of the entire control region. In conclusion, we dem-
onstrate here the existence of an unexpected
mtDNA transcript stabilization mechanism that
almost completely compensates for the severely
reduced transcription initiation in rescue hearts.
Future elucidation of the underlying molecular
mechanism may provide a novel pathway to treat
mitochondrial dysfunction in human pathology.
INTRODUCTION
Mitochondrial diseases are among the most common
forms of human genetic disease. In addition, mitochon-
drial dysfunction is implicated in many diﬀerent types of
human age-associated diseases, e.g. diabetes mellitus type
2, heart failure, neurodegeneration and the ageing process
itself (1,2). A molecular understanding of the regulation of
oxidative phosphorylation capacity is therefore not only
of basic scientiﬁc interest but might provide insights into
diﬀerent types of human diseases and ageing.
The mitochondrial network is responsible for a variety
of metabolic processes including oxidative phosphoryl-
ation, which provides the bulk part of the cellular
energy in the form of ATP (3). The oxidative phosphor-
ylation system is under bipartite genetic control requiring
both nuclear and mtDNA-encoded genes for its biogen-
esis. The two strands of mtDNA contain diﬀerent mito-
chondrial genes and are transcribed from dedicated
promoters; designated the light- and heavy-strand pro-
moters (LSP and HSP). Processing of long primary
polycistronic transcripts releases 13 mRNAs, which all
encode respiratory chain subunits, and 2 rRNAs and
22 tRNAs, which are needed for mitochondrial
translation.
We have previously deﬁned the basal mammalian mito-
chondrial transcription machinery as consisting of three
nuclear-encoded proteins; mitochondrial transcription
factor A (TFAM), mitochondrial RNA polymerase and
mitochondrial transcription factor B2 (TFB2M). This
triad of proteins is suﬃcient and necessary for promoter-
speciﬁc initiation of transcription in a pure recombinant
system (3–6). The TFAM protein is not only an indispens-
able component of the mtDNA transcription machinery
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role for TFAM and its homologues in packaging and
stabilizing mtDNA in a variety of organisms such as
yeast (8), chicken (9), mouse (10) and humans (11,12).
This latter function is consistent with the fact that
TFAM belongs to the high mobility group-box-domain
protein family, which has the capacity to bind, bend and
wrap DNA in a largely sequence-independent manner
(13,14). Furthermore, the yeast homologue of TFAM,
denoted ABF2, is dispensable for mtDNA transcription
but is necessary for mtDNA maintenance (15). In vivo
data from the mouse have demonstrated that disruption
of Tfam leads to lack of mtDNA, which, in turn, causes a
profound respiratory chain deﬁciency and embryonic le-
thality in mid-gestation (16). The human TFAM
(hTFAM) protein has a similar capacity to bind DNA
as the mouse TFAM (mTFAM) protein, but hTFAM is
a poor activator of mtDNA transcription in the mouse
recombinant transcription system (7,10). Consistent with
these in vitro results, we have demonstrated that hTFAM
cannot rescue the embryonic lethality of mTFAM
knockout mice (10). Mouse embryos lacking mTFAM
and expressing hTFAM can maintain near-normal levels
of mtDNA but have very low levels of mitochondrial tran-
scripts and can therefore not sustain normal oxidative
phosphorylation (10). Expression of hTFAM in mice
with normal endogenous mTFAM expression results in
increased mtDNA levels without a signiﬁcant increase of
mtDNA expression, further demonstrating that it is
possible to dissociate mtDNA copy number regulation
from mtDNA transcription (10).
We have previously created a series of tissue-speciﬁc
knockout mice with disruption of Tfam in cardiomyocytes
and demonstrated that such animals develop a progressive
respiratory chain deﬁciency in heart during post-natal life
(17–19). These knockout mice develop a progressive
dilated cardiomyopathy with heart conduction blocks
and die within the ﬁrst months of life. These conditional
knockout mice have provided valuable models for severe
mitochondrial cardiomyopathy, but have not been suited
to model the more moderate decline of respiratory chain
function associated with age-associated heart disease. In
the present study, we therefore used a genetic strategy to
express hTFAM in mice lacking mTFAM expression in
heart; based on the assumption that hTFAM would par-
tially rescue the cardiomyopathy phenotype. Surprisingly,
we report here that hTFAM almost fully complements the
absence of mTFAM in the mouse heart. These rescued
animals have severely decreased de novo transcription of
mtDNA in heart but contain normal levels of mtDNA and
near-normal steady-state levels of the mtDNA-encoded
transcripts. The animals survive and develop normally
with only a minor respiratory chain deﬁciency in the
heart. In addition, we observe high levels of a novel tran-
script spanning the non-coding region of mtDNA, indica-
tive of altered RNA processing. This study thus presents
experimental evidence that a highly specialized and
energy-demanding tissue such as heart can activate com-
pensatory mechanisms to increase the stability of
mtDNA-encoded transcripts if de novo transcription of
mtDNA is severely reduced. This compensation does not
only include regulation of transcript stability but may also
involve alteration of transcription termination events.
MATERIALS AND METHODS
Mouse breeding and genotyping
Previously engineered Tfam
loxP/loxP mice of mixed genetic
background (16) were crossed to transgenic animals ex-
pressing hTFAM from a genomic phage artiﬁcial
chromosome (hTFAM
PAC-tg) transgene (10), generating
Tfam
loxP/loxP; hTFAM
PAC-tg animals [clone PAC19 in ref-
erence (10)]. Mice expressing the P1 phage recombinase,
cre, with a nuclear localization signal (NLS-cre) from the
muscle creatine kinase promoter (Ckmm-NLS-cre) were
crossed to these transgenic Tfam
loxP/loxP; hTFAM
PAC-tg
animals (Supplementary Figure S1). Ear clip DNA from
oﬀspring was genotyped for the PAC transgene, the ﬂoxed
mTfam gene and the Ckmm-NLS-cre gene, as previously
reported (10,16,17).
Mitochondrial preparation
Hearts were collected from 11 to 12-week-old animals and
crude mitochondrial preparations were obtained as
described (20). In brief, the hearts were homogenized in
ice-cold 75mM sucrose, 225mM sorbitol, 1mM EGTA,
0.1% bovine serum albumin (BSA) and 10mM Tris–HCl,
pH7.4, using a Teﬂon pestle homogenizer (six strokes at
1000r.p.m.). Cell membranes and debris were pelleted
twice for 5min at 1000g. The mitochondrial supernatants
were washed three times and pelleted at 12000g.
DNA isolation and Southern blot analysis
Genomic or mitochondrial DNA was isolated by standard
Tris/EDTA/SDS and proteinase K treatment. DNA was
puriﬁed by phenol–chloroform extraction, precipitated
with sodium acetate (NaOAc) and ethanol, and dissolved
in 10mM Tris–HCl pH8.5 or dH2O. Total DNA (3mg)
from heart tissue of either 11- (±1) or 52 (±1)-week-old
animals were digested over night with 20U PstI (New
England Biolabs), precipitated by NaOAc–ethanol pre-
cipitation and used for Southern blotting.
RNA isolation and Northern blot analysis
Genomic or mitochondrial RNA from heart or kidney
preparations was isolated with Trizol reagent
(Invitrogen) or ToTALLY RNA (Ambion), following
the manufacturer’s instructions. RNA quality was
analysed on a BioAnalyser 2100 (Agilent) and an appro-
priate amount of genomic or mtRNA was used for
standard Northern blot analysis. Mt-tRNAs were
separated on a 10% 7M UREA/polyacrylamide gel and
blotted onto a nylon membrane (Amersham) by electrical
transfer.
Probes and labelled oligonucleotides
For double-stranded DNA and single-stranded RNA
probes, appropriate PCR products were cloned into
pCR-II using the pCR-II TOPO cloning kit (Invitrogen).
DNA probes were excised and puriﬁed by gel extraction
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32P]-
dCTP (Amersham) with the prime-it II kit (Stratagene).
For RNA probes, the appropriate vectors were linearized
and in vitro transcribed using Sp6 or T7 polymerase (both
New England Biolabs) in the presence of [a-
32P]-UTP
(Amersham). End-labelled oligonucleotide probes were
generated by polynucleotide kinase treatment (New
England Biolabs) in the presence of [g-
32P] ATP
(Amersham). Probe hybridization was performed in
RapidHyb buﬀer (Amersham) at 65 C (for probes) or
42 C (for oligonucleotides) for at least 90min. After
washing, the membranes were exposed to an autoradiog-
raphy Hyperﬁlm (Amersham), and/or analysed by
phosphor imager analysis (BioRad). A list of primers
and oligonucleotides used is shown in the
Supplementary Table S1.
Isolation of proteins and Western blot analysis
Total protein extracts were generated as previously
described (10). Brieﬂy, tissue homogenates were sus-
pended in equal parts of suspension buﬀer (0.1M NaCl,
0.01M Tris–HCl, pH7.6, 10mM EDTA, 1% Aprotinin,
1% PMSF), and loading buﬀer (0.1M Tris–HCl, pH6.8,
4% SDS, 20% glycerol, 200mM DTT). Samples were
boiled for 10min, sonicated and centrifuged for 10min
at 10000g. The supernatants were collected and protein
concentration determined with a total protein quantiﬁca-
tion kit (Sigma). Western blot analysis was performed as
previously described (10).
Biochemical evaluation of respiratory chain function
and glycolysis
Heart tissue samples of rescued animals (n=5 per age
group) and control animals (n=5 at 12 weeks, and 4 at
52 weeks) were collected at 12 and 52 weeks of age and
mitochondria were isolated. The respiratory chain enzyme
activities and mitochondrial ATP production rate
(MAPR) were measured blind as described (21,22). For
determination of glycolytic enzyme activities, a frozen
sample of heart tissue (10mg) was thawed and analysed
as previously described (17).
Histochemistry was performed on 10-mm sections from
fresh-frozen hearts of 12- and 28-week-old animals as pre-
viously described (22).
In organello transcription assay
De novo transcription was measured in isolated
mitochondria as described previously (23–25).
Mitochondrial preparations were suspended in transcrip-
tion buﬀer, containing 25mM sucrose, 75mM sorbitol,
100mM KCl, 10mM K2HPO4, 50mM EDTA, 5mM
MgCl2, 1mM ADP, 10mM glutamate, 2.5mM malate
and 10mM Tris–HCl (pH7.4), with 1mg BSA per milli-
litre. Mitochondria containing 200mg protein, as
determined by Bradford method (BioRad), were
incubated for 45min in 500ml of transcription buﬀer con-
taining 30mCi [a-
32P]-UTP. After incubation, samples
were pelleted and washed twice in 1ml 10mM Tris–HCl
(pH6.8), 0.15mM MgCl2, containing 10% glycerol.
Mitochondrial RNA was isolated from the ﬁnal pellet
using the ToTALLY RNA isolation kit (Ambion),
followed by Northern blot analysis.
S1 protection assay
S1 nuclease protection was performed essentially as
described (19) following the ribonuclease protection
assay kit III (Ambion) protocol, except that an S1
nuclease (Promega) was used for digestion instead of the
supplied RNases, since DNA oligonucleotides were used
instead of riboprobes. The end-labelled oligonucleotide
probes, against 7S RNA 50-GAC ATA TAA TAT TAA
CTA TCA AAC CCT ATG TCC TGA TCA ATT CTA
GTA GT-30 (mismatch to 7S RNA underlined) and ND6
50-AAT AAA AAT ACC CGC AAA CAA-30, were used
to hybridize to mitochondrial RNA, followed by S1
nuclease digestion and separation on an 8% 7M UREA/
polyacrylamide gel.
Mapping the 30-end of the D-loop transcript
A ligation-mediated reverse transcription protocol was
used to sequence the 30-ends of transcripts. In a 100ml
reaction, 3mg of RNeasy puriﬁcation kit (Qiagen)-
puriﬁed total heart RNA was ligated to 100pmol of
linker: 50-Phosphate-GAA TTC ACT GGC CGT CGT
TTT ACA-spacer C3-30 (antisense to standard M13
forward sequencing primer) using 20U T4 RNA ligase
(New England Biolabs), followed by NaOAc–ethanol pre-
cipitation. First strand reverse transcription was
performed using M13 forward sequencing primer and
the SuperScript
TM
II Reverse Transcriptase kit
(Invitrogen). Second strand ampliﬁcation was performed
using the M13 forward sequencing primer and the
mtDNA-speciﬁc primer 50-TCA AAC CCT ATG TCC
TGA TC-30 (position 16164). The resulting PCR
products were cloned and sequenced in-house on a
3130XL cycle sequencer (Applied Biosystems), using
0.5  big dye v1.1 (Applied Biosystems) in a 20ml reaction.
Ligation-mediated quantitative real-time PCR
Quantiﬁcation of nascent replication strands was per-
formed using a ligation-mediated quantitative real-time
PCR method, as described previously (26). Two independ-
ent extension primers complement to mtDNA sequence
either within the terminated replication strand (primer
W), or within the non-terminated strand (primer E) were
annealed independently to total DNA and extended using
Vent polymerase (New England Biolabs), followed by
ligation of a double-stranded linker/adaptor to the ends
of these extensions. Nested primers to the linker/adaptor
and to sequence complement to both extended strands
were then used to quantify the amount of extensions in
the reaction, using quantitative real-time PCR on a
LightCycler 2.0 (Roche) with FastStart DNA master
SyBr Green 1 mix (Roche). Extension primers E: 50-TAC
ATA AAT TTA CAT AGT AC-30; and W: 50-GGT CAT
AAA ATA ATC ATC AAC-30; linker sequences L1: 50-
GTG ACC CGG GAG ATC TGT ATTC-30; L2: 50-
GAA TAC AGA TC-30; and the common internal
primer L3: 50-ATC CTC CGT GAA ACC AAC AA-30.
Annealing and extension was controlled for, using cloned
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I (position 16027bp in mtDNA). Previous ampliﬁcations
were pooled, gel puriﬁed (Qiagen gel puriﬁcation kit), and
quantiﬁed on a Hoefner DNynaliser, to be used as stand-
ards to evaluate PCR eﬃciency.
RESULTS
hTFAM rescues the cardiac hypertrophy of tissue-speciﬁc
Tfam knockout mice
We have previously generated mice with disruption of
Tfam in heart (17,19); herein referred to as ‘cardiomyop-
athy mice’. In the present study, we investigated whether
the phenotype of such cardiomyopathy mice could
be rescued by expression of the hTFAM protein. Mice
containing a human phage P1 artiﬁcial chromosome
(PAC) transgene, which ubiquitously expresses
hTFAM (10), were crossed into the cardiomyopathy
mice background (Supplementary Figure S1), to gener-
ate mice of the genotype Tfam
loxP/loxP, Ckmm-NLS-cre;
+/hTFAM
PAC-tg, hereafter denoted ‘rescue mice’. Rescue
mice were born at the expected mendelian ratio and
appeared normal at birth. Western blot analyses of hearts
showed very low levels of the mTFAM protein both in
cardiomyopathy and rescue mice, whereas the hTFAM
protein only was detected in rescue hearts (Figure 1A).
The expression of hTFAM was similar in hearts of rescue
mice and hearts of mice expressing both hTFAM and
mTFAM (hereafter denoted TFAM over-expression
mice, OE). The results show that expression of hTFAM
in the mouse heart is not dependent on endogenous
mTFAM levels, and that endogenous mTFAM levels are
not altered if hTFAM is expressed (Figure 1B). Thus, there
seems to be no feedback mechanism to sense total TFAM
levels in cardiomyocytes.
We have previously shown that the cardiomyopathy
mice develop a dilated cardiomyopathy with heart conduc-
tion blocks and die by 10–14 weeks of age (17,19).
Consistent with previous results (17), we found that the
heart weight to body weight ratio was massively increased
in end-stage cardiomyopathy mice at the age of 12 weeks
(Figure 1C). In contrast, rescue mice had normal heart
weight to body weight ratios at all studied ages
(Figure 1C) and survived without obvious disease
symptoms until the age of 62 weeks, when we stopped
observing the animals. Northern blot analysis of atrial
natriuretic factor (ANF) expression, a commonly used mo-
lecular marker for heart failure, showed dramatically
increased ANF transcript levels in the myocardium of car-
diomyopathy mice, whereas only a mild induction of ANF
expression was found in the hearts of rescue mice (Figure
1D). These results thus demonstrate that hTFAM expres-
sion is suﬃcient to almost completely revert the cardiomy-
opathy phenotype of tissue-speciﬁc TFAM knockout mice.
Rescue hearts have decreased de novo transcription of
mtDNA but near-normal steady-state levels of transcripts
We assessed de novo transcription of mtDNA in rescue
heart mitochondria with in organello transcription
assays and found a decrease of at least 45% in comparison
with control heart mitochondria (Figure 2A). Levels of
transcription initiation at LSP were also assessed by S1
mapping of the 7S RNA, which is a good indicator of
de novo transcription of mtDNA (25). There was a
profound decrease of 7S RNA transcripts in rescue
hearts in comparison with control hearts (Figure 2B
and C). The ﬁnding of very low levels of transcription
initiation of mtDNA in hearts of rescue mice is consistent
with the previous biochemical observation that hTFAM is
poor at promoting mtDNA transcription initiation in the
mouse system (10).
The reduced levels of mitochondrial transcription initi-
ation in hearts of rescue animals led us to investigate the
steady-state levels of several transcripts, i.e. cytochrome c
oxidase subunit 1 (COX1), NADH dehydrogenase subunit
6 (ND6) and the large ribosomal RNA (16S rRNA) in
rescue animals. No signiﬁcant changes were observed in
hearts of 12-week-old rescue animals (Figure 2D) and a
moderate decrease of steady-state levels of the COX1
mRNA and the 16S rRNA was present in 52-week-old
rescue animals (Figure 2E). Additional characterization
of transcription patterns in heart from 14-week-old
rescue animals showed normal levels of 12S rRNA,
NADH dehydrogenase subunit 5 (ND5) mRNA and cyto-
chrome b (cytb) mRNA, whereas the levels of NADH de-
hydrogenase subunit 1 (ND1) mRNA were slightly
reduced (Figure 3A). A comprehensive survey of mito-
chondrial tRNAs, transcribed from either LSP or HSP,
showed both increased (tRNA
C and tRNA
Q) and
decreased (tRNA
F and tRNA
L1) steady state-levels
(Figure 3B). The genes whose expression was signiﬁcantly
decreased (16S rRNA, COXI, ND1, tRNA
F, tRNA
L1) are
all transcribed from HSP. It is interesting to note that the
steady-state levels of transcripts generated from LSP were
normal (ND6) or increased (tRNA
C and tRNA
Q) despite
evidence of reduced transcription initiation at this
promoter (low 7S RNA levels). This ﬁnding suggests
that levels of transcripts are regulated at a stage following
transcription initiation at LSP, e.g. by reduced transcrip-
tion termination downstream of LSP or by increased sta-
bility of mature transcripts.
Rescue mice have reduced mtDNA replication, but
near-normal steady-state levels of mtDNA
Transcription is a prerequisite for initiation of mtDNA
replication (3) and we therefore investigated mtDNA rep-
lication by assaying levels of the nascent 7S DNA, which
is continuously generated de novo by an abortive mtDNA
replication process in the non-coding displacement (D)
loop region. We used a ligation-mediated PCR technique
to quantify 7S DNA formation in relation to
leading-strand replication (26). Heart mitochondria
isolated from rescue mice had  75% reduction of 7S
DNA molecules (Figure 4A) indicating a decrease in
mtDNA replication initiation consistent with the
observed reduction in transcription initiation (Figure 2A
and B).
Loss of TFAM protein leads to severe mtDNA deple-
tion in cardiomyopathy mice at 12 weeks of age, whereas
Tfam heterozygous knockout hearts have  60% of
6580 Nucleic Acids Research, 2010,Vol.38, No. 19normal mtDNA levels. The rescue mice have near-normal
levels of mtDNA in their hearts at 12 (Figure 4B) and
52 weeks of age (data not shown). These ﬁndings demon-
strate that hTFAM is a good substitute for mTFAM as an
mtDNA maintenance factor.
Rescue mice have decreased COX activity and decreased
ATP production
We performed COX-succinate dehydrogenase
(COX-SDH) double staining on fresh-frozen sections of
hearts from 10-week-old cardiomyopathy, rescue and
control animals (Figure 5A). The cardiomyopathy hearts
displayed many COX negative cells, which stained
strongly for SDH, consistent with previous reports
(18,19). Surprisingly, the rescue hearts also contained
COX negative cells, albeit much less abundant than in
the cardiomyopathy hearts. No COX negative cells were
observed in control hearts. In order to determine whether
the presence of COX negative cells was a temporary phe-
nomenon associated with the switch between mTFAM
and hTFAM at 10 weeks, we also stained sections from
rescue and control mice at 28 weeks of age. No COX
negative cells could be observed in control hearts, while
rescue hearts contained some COX negative cells, but at
lower frequency than at 10 weeks of age (Supplementary
Figure S2).
The respiratory chain dysfunction in rescue hearts, as
detected by the COX-SDH double staining, was further
investigated by biochemical measurements of mitochon-
drial enzyme activities at both 12 and 52 weeks of age.
No changes in citrate synthase activity (CS) were found,
indicating that the transgenic animals had similar mito-
chondrial mass as control animals (Figure 5B).
Biochemical measurements demonstrated an isolated
COX deﬁciency at 12 weeks and tendency to reduction
at 52 weeks in relation to CS activity (Figure 5B). In
contrast, the activity of the exclusively nuclear-encoded
complex II (SDH) was signiﬁcantly increased at 52
weeks, but normal at 12 weeks. We measured the
MAPR in freshly isolated heart mitochondria, both in
relation to CS activity (Figure 5C) and in relation to
heart tissue mass (Supplementary Figure S3). The
MAPR/CS in heart tissue of rescued mice was reduced
with substrates entering at all levels of the respiratory
chain, with the exception of succinate, which enters the
respiratory chain at complex II. The general decrease in
ATP production rate in the heart tissue of rescue animals
is consistent with an inhibition at the level of complex IV
(COX).
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Figure 1. hTFAM can compensate for loss of mTFAM in the heart. (A) Western blot analysis of total heart protein extracts using polyclonal
antibodies against mouse and hTFAM, demonstrating severe reduction of the mTFAM protein in both cardiomyopathy (KO) and rescue (R)
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the ANF, as determined by Northern blot analysis. Values are given as percentage of controls. Data are presented as means±SEM; *P<0.05;
***P<0.001, respectively.
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encompassing the non-coding region
We performed Northern blot analyses and found that the
rescue hearts contained an abundant transcript of  1kb
in length encompassing the D-loop region.
Characterization with strand-speciﬁc RNA probes and
RNase I treatment revealed that this transcript corres-
ponded to a transcript complementary to the heavy
strand (Figure 6A and B) and we therefore termed this
transcript anti-control region (ACR) transcript. This tran-
script has the opposite sense as the LSP transcript
providing primers for initiation of mtDNA replication.
The ACR transcript was not detected in the kidney of
heart rescue animals or in hearts from animals expressing
both mTFAM and hTFAM (Figure 6B). The presence of
this transcript is thus dependent on both the presence of
hTFAM and the absence of mTFAM.
The 50-terminus of the ACR transcript was mapped to
immediately upstream tRNA
P by primer extension (data
not shown) and by Northern blot analysis with
radiolabelled oligonucleotide probes corresponding to
the heavy strand of the control region (Figure 6A and
C). The 30-terminus of the ACR transcript was identiﬁed
by ligation-mediated reverse transcription PCR followed
by cloning and sequencing. The 30-terminus could be pre-
cisely aligned immediately upstream of tRNA
F (position
16297–16299) and contained a polyadenylation tail of at
least 50nt (Supplementary Figure S4). The exact nucleo-
tide position is uncertain as the two most proximal bases
in the mouse mtDNA genome are adenine nucleotides and
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protection assay of LSP proximal transcription (7S RNA) and control transcript (ND6) of control (C) and rescue (R) mitochondrial RNA extracts.
(D and E) Relative transcript levels normalized to the nuclear 18S rRNA transcript. Levels of the mitochondrial transcripts of COX1 (light grey bars)
and ND6 (dark grey bars) and the large mitochondrial ribosomal subunit 16S rRNA (white bars) are shown at 12 (D) and 52 weeks (E). Data are
presented as means±SEM percentage of controls; *P<0.05; ***P<0.001, respectively.
6582 Nucleic Acids Research, 2010,Vol.38, No. 19thus could be generated either by polyadenylation or tran-
scription. On the other hand, oligonucleotide probes com-
plementary to control region light strand transcripts failed
to show any diﬀerence between the rescue and control
samples (data not shown). In summary, mitochondrial
transcription in rescue hearts generates high levels of a
polyadenylated transcript, which extends from tRNA
P at
the 50-end to tRNA
F at its 30-end and thus has a length of
943nt (excluding the poly A tail).
The presence of the ACR transcript correlated with the
loss of a short RNA species (* in Figure 6C) present in
control animals. This shorter transcript extends between
the tRNA
T and the onset of the termination-associated
sequence (TAS) region. This is consistent with the sugges-
tion that a normally occurring transcription termination
event close to the TAS region is lost in rescue hearts. We
performed in vitro transcription run oﬀ assays using both
mouse and hTFAM in a reconstituted mouse transcription
assay. However, no transcription termination due to the
presence of TFAM could be observed under these condi-
tions (Figure 6D). We also failed to identify any speciﬁc
diﬀerences in hTFAM and mTFAM binding at or near
the TAS region by in vitro footprinting analysis (data not
shown). In order to investigate whether transcription
proceeds into tRNA
F, we performed qRT-PCR experi-
ments across HSP. No increase in transcript could be
identiﬁed in this region (data not shown).
We wondered if the increased expression of the ACR
transcript was a late secondary response to the increased
physiological stress on heart mitochondria lacking
mTFAM. We thus investigated the steady-state levels of
ACR, COX1 and ND1 transcripts in heart mitochondria
from 4- to 10-week-old animals. As expected, the cardio-
myopathy mice have decreased mitochondrial transcripts
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animals retain close to normal transcript levels and
express the ACR transcript from at least 4 weeks of age.
DISCUSSION
We demonstrate here that severely reduced transcription
of mtDNA can be unexpectedly well tolerated in
cardiomyocytes, a highly specialized cell type with a con-
tinuous high demand for energy. This ﬁnding is surprising
and points towards the existence of substantial
post-transcriptional regulatory mechanisms. Expression
of hTFAM in mTFAM knockout hearts almost fully
rescues the cardiomyopathy phenotype despite the fact
that hTFAM is a very poor transcriptional activator in
the mouse. The rescue mice have close to normal
mtDNA levels but severely decreased de novo transcrip-
tion of mtDNA. Thus, we were able to demonstrate a
clear dissociation of mtDNA transcription and mtDNA
maintenance. These ﬁndings also show that a severe re-
duction in transcription initiation allows maintenance of
near-normal mtDNA levels. However, the decrease in
transcription initiation has only a minor impact on
steady-state levels of mitochondrial transcripts and there
is only a slight decrease of respiratory chain function.
Biochemical measurements of the activities of individual
respiratory chain complexes revealed a decrease of COX
activity, whereas the activities of the other complexes were
normal or, in case of SDH even increased. Measurement
of MAPR with substrates entering the respiratory chain at
diﬀerent complexes also gave a pattern consistent with a
moderate COX deﬁciency. Enzyme histochemical staining
of heart tissue sections supported the biochemical results
and showed the presence of COX-deﬁcient cells. These
ﬁndings indicate that COX is particularly sensitive to a
moderate reduction in mtDNA expression.
Cardiomyopathy mice lacking mTFAM in heart have
increased heart weight and a massively increased expres-
sion (30-fold) of ANF, a commonly used marker for heart
failure (27). However, the rescue animals have normal
heart weight and only a moderate induction of ANF ex-
pression (5-fold), indicating that these animals only suﬀer
from minor heart failure. It is possible that the reduced
cardiac function observed during ageing, at least in part,
stem from a reduced oxidative phosphorylation capacity
of cardiac mitochondria. Microarray studies have shown
an age-related decrease in the expression of genes involved
in metabolism and respiratory chain function in tissues
such as heart, skeletal muscle and brain (28–31).
Observations made in hearts of senescent rats and ﬂies
show a reduced rate of mitochondrial transcription
without aﬀecting mtDNA copy number (32,33). Also,
reduced 12S rRNA and COX1 transcript levels were
found in hearts, cerebral hemispheres and cerebellum,
but not in the liver, of senescent rats (34). However, a
causal role of decreased mitochondrial transcription
capacity has not been established in age-associated cardio-
vascular disease or in the ageing process itself.
We were able to show here that rescue hearts have
severely reduced transcription initiation at LSP, but sur-
prisingly retain normal ND6 and normal to increased
tRNA levels. Total de novo transcription was also
reduced and manifested itself with the reduction of the
HSP-derived ND1, COX1 and 16S transcripts. How
rescued mitochondria are able to maintain normal ND6
transcript levels is unclear, but a signiﬁcant increase in
transcript stability would be a plausible mechanism.
Increased stability is supported by the observations
that tissue-speciﬁc TFAM KO mice rapidly loose
TFAM protein levels and mtDNA levels, but can retain
mitochondrial transcripts for weeks and months after dis-
appearance of TFAM in the targeted tissue (22,35).
Interestingly, we found a novel heavy strand transcript
covering the D-loop region in hearts of rescue animals that
is expressed from at least 4 weeks of age. Several groups
have previously reported heavy strand transcripts of the
D-loop region. For instance, Aloni and Attardi (36)
reported that almost the entire heavy strand of HeLa
cells was transcribed and several transcription termination
events have been reported between tRNA
P and TAS (37).
In this latter study, the authors identiﬁed transcripts of up
to 800nt in length, corresponding to almost the entire
D-loop region. Later it was suggested that mitochondrial
HSP transcription passes through the entire length of the
control region, and is terminated downstream of HSP, due
to the presence of a putative polyadenylation signal (38),
and an unidentiﬁed termination factor (39). Avadhani and
colleagues (39) suggested that this mode of transcription
termination is the normal mode of mitochondrial HSP
transcription termination, and the D-loop transcript is
rapidly degraded under normal physiological conditions.
Here, we report the up-regulation of a transcript with
identical 30 end as observed by Avadhani and colleagues.
The up-regulation of this transcript could be explained by
several mechanisms.
This transcript could be the result of either speciﬁc or
global transcription stabilization events in heart rescue
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Figure 4. mtDNA replication and maintenance (A) The normalized
ratios of steady-state levels of replication termination versus replication
elongation events of control (C; N=7) and rescue (R; N=5) heart
samples, as determined by quantitative real-time PCR are shown. Data
are presented as means±SEM percentage of controls; *P<0.05. (B)
Southern blot analysis of mtDNA copy number in comparison with
18S DNA demonstrate a signiﬁcant reduction of mtDNA levels in KO
(8%; N=7) and heterozygous KO (HET) (62%; N=3), and a modest
reduction in R (80%; N=8; P=0.075) in comparison with control
samples (N=10).
6584 Nucleic Acids Research, 2010,Vol.38, No. 19mice. The ACR transcript has previously been reported in
HepG2 cells, in which mitochondrial protein synthesis had
been blocked by the addition of thiamphenicol (40).
Thiamphenicol treatment leads to increased mitochondrial
transcription, with a maximal induction 3 days after drug
treatment. Interestingly, this D-loop transcript—termed
RNA DL-L by the authors—was induced only 7 days
after initiating drug treatment and was thus not due to
increased transcription. One plausible explanation
for this is that mitochondria responding to high
demands of gene expression undergo a switch in the regu-
lation of transcription, enabling transcription through the
regulatory D-loop region. Unfortunately, we were unable
to detect transcripts containing both control region
and downstream RNA sequence, suggesting either the
absence of such a product or very rapid processing at
this site.
Instead, we observed a short RNA species, ranging
from the region complementary to the tRNA
P gene to
the TAS region in control animals but not in rescue
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Nucleic Acids Research, 2010,Vol.38, No. 19 6585animals, which instead express the larger ACR transcript.
The termination-associated region is comprised in the
mouse of two blocks spanning 107nt (41). We propose
that the TAS region, previously identiﬁed as a putative
termination site for heavy strand replication, is also the
site for HSP transcription termination under normal
physiological conditions. The absence of transcription ter-
mination in the present mouse model could either be due
to the failure of hTFAM to promote termination, or
caused by a switch in transcription regulation. It is note-
worthy that there are diﬀerent eﬀects on LSP-dependent
transcripts upstream and downstream of this postulated
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6586 Nucleic Acids Research, 2010,Vol.38, No. 19termination event. Levels of 7S RNA, which is proximal
to the promoter, are decreased, whereas the levels of
tRNA
C and tRNA
Q are increased in the heart rescue
animals. This observation could be explained by increased
transcript stability of tRNA
C and tRNA
Q, but two obser-
vations argue against this interpretation. First, increased
stability would imply that there is a diﬀerence in RNA
stability regulation between LSP- and HSP-initiated tran-
scripts, which we ﬁnd unlikely. Second, we have previous-
ly reported that tRNA levels reﬂect overall transcription
rates and are not regulated by RNA stability to the same
extent as are mitochondrial mRNA molecules (24,25). It is
therefore possible that a decrease of transcription termin-
ation in the TAS region is compensating for a decrease in
transcription initiation at LSP. This termination event ap-
parently regulates transcription termination in a bidirec-
tional way, since we see an up-regulation of the ACR
transcript. It is possible that the ACR transcript has a
speciﬁc functional role of its own, which remains to be
established, but it is also possible that it simply is a sec-
ondary consequence of decreased termination of
LSP-dependent transcripts in the TAS region.
Additional factors are required to promote transcrip-
tion termination, since both hTFAM and mTFAM
failed to promote transcription termination in a pure re-
combinant in vitro transcription system. Isolating the
factors required for transcription termination in vivo,
and whether alterations in the mechanism of transcription
termination are associated with various disease states or
developmental stages, will be an important step in under-
standing mitochondrial transcription. We previously
demonstrated that hearts of TFAM KO mice undergo a
genetic switch, reinitiating a fetal gene expression pro-
gramme and activating mitochondrial biogenesis (17).
Potentially, such a switch in transcription regulation
might also occur, under milder mitochondrial stress.
In conclusion, we were able to demonstrate that in vivo
mechanisms exist compensating for reduced mtDNA tran-
scription in highly energy demanding tissues, such as the
heart. Further, we report that heavy-strand transcription
of mtDNA regularly terminates at TAS.
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